Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways

References

• Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol. Ther.1, 599–606 (2002).
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov.4, 988–1004 (2005).
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science297, 63–64 (2002).
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res.68, 3077–3080; discussion 3080 (2008).
   PubMed Web of Science ®Google Scholar
• Simon R. The use of genomics in clinical trial design. Clin. Cancer Res.14, 5984–5993 (2008).
   PubMed Web of Science ®Google Scholar
• Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res.14, 5967–5976 (2008).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20, 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Hu X, Stern HM, Ge L et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res.7, 511–522 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson PH, Esteva FJ. The use of HER2 modulation in the adjuvant setting. Curr. Oncol. Rep.9, 9–16 (2007).
   Google Scholar
• Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest.105, 3–7 (2000).
   PubMed Web of Science ®Google Scholar
• Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood112, 4808–4817 (2008).
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol.25, 587–595 (2007).
   PubMed Web of Science ®Google Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol.26, 60–70 (1999).
   PubMed Web of Science ®Google Scholar
• Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene18, 2241–2251 (1999).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nat. Med.2, 561–566 (1996).
   PubMed Web of Science ®Google Scholar
• Bos JL. Ras oncogenes in human cancer: a review. Cancer Res.49, 4682–4689 (1989).
   PubMed Web of Science ®Google Scholar
• Campbell PM, Singh A, Williams FJ et al. Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis. Methods Enzymol.407, 195–217 (2006).
   Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Li N, Batt D, Warmuth M. B-Raf kinase inhibitors for cancer treatment. Curr. Opin. Investig. Drugs.8, 452–456 (2007).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA105, 3041–3046 (2008).
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Herter S, Tien J et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res.69, 3042–3051 (2009).
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman J et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol.27, 15s (2009).
   Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA et al.BRAF mutation predicts sensitivity to MEK inhibition. Nature439, 358–362 (2006).
   PubMed Web of Science ®Google Scholar
• Ball DW, Jin N, Rosen DM et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J. Clin. Endocrinol. Metab.92, 4712–4718 (2007).
   PubMed Web of Science ®Google Scholar
• Friday BB, Yu C, Dy GK et al.BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res.68, 6145–6153 (2008).
   PubMed Web of Science ®Google Scholar
• Yeh JJ, Routh ED, Rubinas T et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol. Cancer Ther.8, 834–843 (2009).
   PubMed Web of Science ®Google Scholar
• Dougherty MK, Muller J, Ritt DA et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell.17, 215–224 (2005).
   PubMed Web of Science ®Google Scholar
• Hall-Jackson CA, Eyers PA, Cohen P et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol.6, 559–568 (1999).
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, O‘Brien C, Boyd Z et al.In vivoantitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res.15, 4649–4664 (2009).
   PubMed Web of Science ®Google Scholar
• Mirzoeva OK, Das D, Heiser LM et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res.69, 565–572 (2009).
   PubMed Web of Science ®Google Scholar
• Dummer R, Robert C, Chapman P et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, Phase II study. J. Clin. Oncol.26, (2008).
   Web of Science ®Google Scholar
• Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin. Cancer Res.12, S2301–S2307 (2006).
   PubMed Web of Science ®Google Scholar
• Simi L, Pratesi N, Vignoli M et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol.130, 247–253 (2008).
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med.14, 1351–1356 (2008).
   PubMed Web of Science ®Google Scholar
• Jia S, Liu Z, Zhang S et al. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis. Nature454, 776–779 (2008).
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene27, 5497–5510 (2008).
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol.3, 317–330 (2003).
   PubMed Web of Science ®Google Scholar
• Sasaki T, Suzuki A, Sasaki J, Penninger JM. Phosphoinositide 3-kinases in immunity: lessons from knockout mice. J. Biochem.131, 495–501 (2002).
   PubMed Web of Science ®Google Scholar
• Ihle NT, Lemos R, Jr., Wipf P et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res.69, 143–150 (2009).
   PubMed Web of Science ®Google Scholar
• Torbett NE, Luna-Moran A, Knight ZA et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J.415, 97–110 (2008).
   PubMed Web of Science ®Google Scholar
• Serra V, Markman B, Scaltriti M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res.68, 8022–8030 (2008).
   PubMed Web of Science ®Google Scholar
• Raynaud FI, Eccles SA, Patel S et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther.8, 1725–1738 (2009).
   PubMed Web of Science ®Google Scholar
• Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet.21, 99–102 (1999).
   PubMed Web of Science ®Google Scholar
• Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res.6, 880–886 (2000).
   PubMed Web of Science ®Google Scholar
• Fletcher JA, Rubin BP. KIT mutations in GIST. Curr. Opin. Genet. Dev.17, 3–7 (2007).
   PubMed Web of Science ®Google Scholar
• Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs16, 461–466 (2005).
   PubMed Web of Science ®Google Scholar
• Carpten JD, Faber AL, Horn C et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature448, 439–444 (2007).
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res.68, 6084–6091 (2008).
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Lu Y, Poradosu E et al. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res.13, 7421–7431 (2007).
   PubMedGoogle Scholar
• She QB, Chandarlapaty S, Ye Q et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One3, e3065 (2008).
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Yap TA, Fearen I et al. A Phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients with advanced solid tumor. J. Clin. Oncol.27(15), 3503 (2009).
   PubMedGoogle Scholar
• Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin. Investig. Drugs17, 1717–1734 (2008).
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Clark BA 3rd, Alexandrescu DT. mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. Expert Opin. Investig. Drugs18, 175–187 (2009).
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2. J. Biol. Chem.283, 34495–34499 (2008).
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol.27, 2630–2637 (2009).
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science307, 1098–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Feldman ME, Apsel B, Uotila A et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol.7, e38 (2009).
   PubMed Web of Science ®Google Scholar
• Guertin DA, Stevens DM, Saitoh M et al. mTOR complex 2 is required for the development of prostate cancer induced by PTEN loss in mice. Cancer Cell15, 148–159 (2009).
   PubMed Web of Science ®Google Scholar
• Sakatani T, Onyango P. Oncogenomics: prospects for the future. Expert Rev. Anticancer Ther.3, 891–901 (2003).
   Google Scholar
• Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer6, 735–741 (2006).
   PubMed Web of Science ®Google Scholar
• Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature439, 353–357 (2006).
   PubMed Web of Science ®Google Scholar
• Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med.12, 1294–1300 (2006).
   PubMed Web of Science ®Google Scholar
• Saal LH, Johansson P, Holm K et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl Acad. Sci. USA104, 7564–7569 (2007).
   PubMed Web of Science ®Google Scholar
• Singh A, Greninger P, Rhodes D et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell15, 489–500 (2009).
   PubMed Web of Science ®Google Scholar
• Petricoin EF 3rd, Bichsel VE, Calvert VS et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J. Clin. Oncol.23, 3614–3621 (2005).
   PubMed Web of Science ®Google Scholar
• Espina V, Liotta LA, Petricoin EF 3rd. Reverse-phase protein microarrays for theranostics and patient tailored therapy. Methods Mol. Biol.520, 89–105 (2009).
   PubMedGoogle Scholar
• Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. Nat. Clin. Pract. Oncol.3, 256–268 (2006).
   PubMedGoogle Scholar
• Wulfkuhle JD, Speer R, Pierobon M et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J. Proteome Res.7, 1508–1517 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis18, 533–537 (1997).
   PubMed Web of Science ®Google Scholar
• Celis JE, Kruhoffer M, Gromova I et al. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett.480, 2–16 (2000).
   PubMed Web of Science ®Google Scholar
• Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol.17, 994–999 (1999).
   PubMed Web of Science ®Google Scholar
• Nishizuka S, Charboneau L, Young L et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA100, 14229–14234 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou J, Wulfkuhle J, Zhang H et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. USA104, 16158–16163 (2007).
   PubMed Web of Science ®Google Scholar
• Boyd ZS, Wu QJ, O’Brien C et al. Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol. Cancer Ther.7, 3695–3706 (2008).
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Schmidt K, Donehower R, Diaz LA Jr. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J. Natl Cancer Inst.101, 1284–1285 (2009).
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med.359, 366–377 (2008).
   PubMed Web of Science ®Google Scholar
• Yen LC, Yeh YS, Chen CW et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin. Cancer Res.15, 4508–4513 (2009).
   PubMed Web of Science ®Google Scholar
• Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature450, 1235–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Jhawer M, Goel S, Wilson AJ et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res.68, 1953–1961 (2008).
   PubMed Web of Science ®Google Scholar
• Loupakis F, Pollina L, Stasi I et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J. Clin. Oncol.27, 2622–2629 (2009).
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell12, 395–402 (2007).
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell6, 117–127 (2004).
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. Clin. Colorectal Cancer8, 135–140 (2009).
   PubMed Web of Science ®Google Scholar
• Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J.15, 110–113 (2009).
   Google Scholar
• Lievre A, Laurent-Puig P. Genetics: predictive value of KRAS mutations in chemoresistant CRC. Nat. Rev. Clin. Oncol.6, 306–307 (2009).
   Google Scholar
• Cross J. DxS Ltd. Pharmacogenomics9, 463–467 (2008).
   PubMed Web of Science ®Google Scholar
• Hebbar M, Wacrenier A, Desauw C et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs17, 855–857 (2006).
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov.3, 711–715 (2004).
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Verweij J. The price of success: cost–effectiveness of molecularly targeted agents. Clin. Pharmacol. Ther.85, 136–138 (2009).
   PubMedGoogle Scholar
• Ray T. Mass general hospital to genetically test all cancer patients within one year. Pharmacogenomics Reporter (2009).
   Google Scholar
• Board RE, Thelwell NJ, Ravetto PF et al. Multiplexed assays for detection of mutations in PIK3CA. Clin Chem.54, 757–760 (2008).
   PubMed Web of Science ®Google Scholar